Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature

18 Feb 2022

Abstract excerpt

The metastatic potential of estrogen receptor (ER)-positive breast cancers is heterogeneous and distant recurrences occur months to decades after primary diagnosis. We have previously shown that patients with tumors classified as ultralow risk by the 70-gene signature have a minimal long-term risk of fatal breast cancer. Here, we evaluate the previously unexplored underlying clinical and molecular characteristics...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Breast Cancer Treatment Studies
Share to Cancer Genomics and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35179782
DOI: 10.1002/ijc.33969

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signaturePMID 35179782Read ↗

Clinical and Molecular Characteristics of ER-Positive Breast Cancer Tumors Identified as Ultralow Risk by the 70-Gene Signature in a Randomized Clinical TrialSemantic proximity Read ↗

MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patientsSemantic proximity Read ↗

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.Semantic proximity Read ↗

<p class="MDPI12titleori1" style="mso-line-height-alt: 14.0pt;"><span style="mso-bidi-font-size: 18.0pt; mso-bidi-font-weight: bold;">MammaPrint™ Genetic Signature in the Brazilian Population, Analysis of Results and Clinical Outcomes (AGEMA-BRA) – Real World StudySemantic proximity Read ↗

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signatureSemantic proximity Read ↗

Prediction of the 70-gene signature (MammaPrint) high versus low risk by nomograms among axillary lymph node positive (LN+) and negative (LN-) Chinese breast cancer patients, a retrospective studySemantic proximity Read ↗

The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of ageSemantic proximity Read ↗

Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancerSemantic proximity Read ↗

A breast cancer gene signature for indolent disease.Semantic proximity Read ↗

Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast CancerSemantic proximity Read ↗

Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patientsSemantic proximity Read ↗

Basal-like breast cancer: molecular profiles, clinical features and survival outcomesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.